(Press-News.org) SAN FRANCISCO-- The new weight loss drug lorcaserin (Belviq) appears to improve blood sugar control in nondiabetic, overweight individuals, independent of the amount of weight they lose, a new study finds. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.
Lorcaserin activates a serotonin receptor (5HT2C) in the brain believed to decrease appetite and promote a sense of fullness, thus encouraging decreased food consumption, said the study's principal investigator, Louis Aronne, MD, professor of clinical medicine at Weill Cornell Medical College, New York City.
"This analysis supports the possible role that the drug's serotonin receptor activation may play in regulating glucose [blood sugar] metabolism," Aronne said.
The U.S. Food and Drug Administration approved lorcaserin last June as an add-on treatment to diet and exercise for long-term weight management in adults who are obese (body mass index, or BMI, greater than 30 kg/m2), or overweight (BMI of 27 or greater) with at least one weight-related health complication.
Aronne's study was a pooled analysis of two previously published clinical trials that together included more than 6,300 overweight or obese, nondiabetic patients. These trials compared the effects of lifestyle changes—diet and exercise—combined with either lorcaserin treatment or a placebo (dummy pill).
The new study received funding from San Diego-based Arena Pharmaceuticals, the maker of lorcaserin, and from Eisai in Woodcliff Lake, N.J.
As a group, the 3,195 patients treated with lorcaserin tablets lost twice as much weight after one year of treatment and lifestyle changes than the 3,185 patients in the placebo group did: an average of 12.8 pounds versus 5.6 pounds, the study authors reported. However, even when lorcaserin-treated patients and placebo-treated patients lost the same amount of weight, those receiving lorcaserin had a greater average decrease (improvement) in their hemoglobin A1c level than the other group did, Aronne said. Hemoglobin A1c is a measure of long-term glycemic (blood sugar) control.
"More than just weight loss alone may explain the significant improvement in glycemic control associated with lorcaserin," Aronne said.
Fasting blood sugar levels also were better after one year in the lorcaserin group, which had an average decrease since the study started of 0.23 milligrams per deciliter (mg/dL), according to the abstract. In the placebo group, fasting blood sugar levels rose 0.60 mg/dL in the same period.
In a separate study not included in this analysis, lorcaserin also demonstrated improved blood glucose measures in patients with type 2 diabetes, Aronne said.
The two earlier studies included in the new analysis were the BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) Study and BLOSSOM (Behavioral modification and Lorcaserin Second Study for Overweight and Obesity Management). The pooled data confirmed the independent findings of BLOOM and BLOSSOM, Aronne said.
###
Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter.
Weight loss drug added to diet and exercise improves blood sugar control
2013-06-17
ELSE PRESS RELEASES FROM THIS DATE:
Source of tumor growth in aggressive prostate cancer found
2013-06-17
SAN FRANCISCO-Researchers have discovered a molecular switch that explains, at least in part, how some fast-growing prostate cancers become resistant to hormone treatment, a new study conducted in human cell cultures and mice finds. The results were presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.
A factor not normally found in the prostate, called Steroidogenic Factor 1, stimulates production of new steroid hormones and increases cell multiplication to fuel growth of the tumor, researchers from the University of Wisconsin-Madison, found.
"This ...
Excessive salt consumption appears to be bad for your bones
2013-06-17
SAN FRANCISCO-- A high-salt diet raises a woman's risk of breaking a bone after menopause, no matter what her bone density is, according to a new study that will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.
The Japanese study found that older women who consumed the highest amount of sodium had more than four times the risk of a nonvertebral fracture, or fracture at any site other than the spine. That finding held true even after the researchers made adjustments for many other characteristics that could affect fracture risk, said ...
Whole body vibration therapy increases bone strength
2013-06-17
SAN FRANCISCO-- A treatment known as whole body vibration therapy significantly increases bone strength among adolescents with cerebral palsy, a new clinical trial from New Zealand shows. The results were presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.
Cerebral palsy affects more than half a million people in the United States. Caused by brain damage around the time of birth, the disorder affects muscle tone and movement, which can severely decrease the quality of life by making walking and other daily activities difficult. As movement ...
Osteoporosis drug may help treat advanced hormone-sensitive breast cancer
2013-06-17
A new osteoporosis drug hinders the growth of estrogen-sensitive cancer that has become resistant to treatment with tamoxifen, a study in mice shows. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.
The medication, bazedoxifene, which is approved in Europe under the brand name Conbriza for the treatment and prevention of postmenopausal osteoporosis, also reduced estrogen activity and estrogen receptor levels in cultured human breast cancer cells, the study authors reported.
"Bazedoxifene, a known, safe drug approved ...
'Gene signature' test diagnoses benign thyroid growths
2013-06-17
A new genetic test accurately and consistently diagnoses benign growths, or nodules, on the thyroid gland, according to a study from Chile. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.
"We have developed a 'gene signature' that effectively identifies benign thyroid nodules," said Hernan Gonzalez, MD, PhD, associate professor at the Pontifical Catholic University of Chile in Santiago. "This test is potentially useful to identify patients who do not require surgery."
The thyroid gland, located in the front of ...
Steroid hormone may be indicator of infant distress
2013-06-17
During labor and delivery, infants preferentially secrete a different stress hormone than their mothers do, according to a new clinical study. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco and published in the open access journal, PLoS One.
A primary component of good pregnancy care is the ability to quickly recognize and respond to fetal distress. Since the stress hormone cortisol is found in much higher concentrations than the hormone corticosterone, it has received greater attention as an indicator of stress ...
Dietary supplement linked to increased muscle mass in the elderly
2013-06-17
SAN FRANCISCO-- A supplemental beverage used to treat muscle-wasting may help boost muscle mass among the elderly, according to a new study. The results were presented today at The Endocrine Society's 95th Annual Meeting in San Francisco.
The supplemental beverage, called Juven®, contains three amino acids, including arginine. Amino acids are the building blocks of proteins, and are required for cell growth and repair. The amino acid arginine is especially important because it increases growth-hormone production, which causes the body to produce a critical protein called ...
Drugs used to treat heart failure and high blood pressure may help decrease obesity
2013-06-17
SAN FRANCISCO-- A type of drug normally used to treat heart failure and high blood pressure helped prevent weight gain and other complications related to a high-fat diet in an animal study. The results were presented today at The Endocrine Society's 95th Annual Meeting in San Francisco.
Weight gain, especially around the waist, and high blood pressure, combine with other abnormalities to form a cluster of diseases known as metabolic syndrome, which increases the risk of heart disease, diabetes and other serious illnesses. With obesity rates climbing in developed countries ...
Too little sleep may trigger the 'munchies' by raising levels of an appetite-controlling molecule
2013-06-17
SAN FRANCISCO--Insufficient sleep may contribute to weight gain and obesity by raising levels of a substance in the body that is a natural appetite stimulant, a new study finds. The results were presented today at The Endocrine Society's 95th Annual Meeting in San Francisco.
The researchers found that when healthy, lean, young adults received only 4.5 hours of sleep a night, they had higher daytime circulating, or blood, levels of a molecule that controls the pleasurable aspects of eating, compared with when they slept 8.5 hours.
"Past experimental studies show that ...
Weight loss improves memory and alters brain activity in overweight women
2013-06-17
SAN FRANCISCO-- Memory improves in older, overweight women after they lose weight by dieting, and their brain activity actually changes in the regions of the brain that are important for memory tasks, a new study finds. The results were presented today at The Endocrine Society's 95th Annual Meeting in San Francisco.
"Our findings suggest that obesity-associated impairments in memory function are reversible, adding incentive for weight loss," said lead author Andreas Pettersson, MD, a PhD student at Umea University, Umea, Sweden.
Previous research has shown that obese ...